Lebrikizumab联合外用糖皮质激素长期治疗中重度特应性皮炎:日本68周III期随机双盲安慰剂对照试验(ADhere-J)
ADhere-J研究评估lebrikizumab联合外用糖皮质激素(TCS)治疗日本中重度特应性皮炎患者至第68周的长期疗效与安全性。第16周应答者继续接受lebrikizumab 250 mg每2周或每4周联合TCS,第68周时66-81%维持IGA(0,1)且较基线改善≥2分,83-89%维持EASI 75;第16周无应答者接受lebrikizumab每2周联合TCS后32-38%达到IGA(0,1),71-80%达到EASI 75。未报告新的安全性信号,多数不良事件为轻中度。
要点
- 第16周应答者继续lebrikizumab联合TCS至第68周,多数可维持IGA(0,1)和EASI 75应答。
- 第16周无应答者继续lebrikizumab每2周联合TCS后仍可逐步改善,至第68周部分达到主要终点。
- 长期安全性与此前全球研究一致,未报告新的安全性信号,多数不良事件为轻中度。
核心结论
- 结果支持在日本人群中长期使用lebrikizumab联合TCS治疗中重度特应性皮炎。
研究设计与样本
- ADhere-J为随机双盲安慰剂对照III期研究,纳入≥12岁、体重≥40 kg的中重度特应性皮炎患者,诱导期16周后进入维持期至第68周。
- 第16周应答者进入维持 primary 人群(MPP),接受lebrikizumab 250 mg每2周或每4周联合TCS;第16周符合方案无应答者进入维持escape人群(MEP),接受lebrikizumab 250 mg每2周联合TCS。
- 主要终点包括第68周时IGA(0,1)且较基线改善≥2分以及EASI 75;其他结局包括生活质量、瘙痒和血清胸腺激活调节趋化因子。
- 试验注册号ClinicalTrials.gov NCT04760314。
主要发现
- 第68周时,MPP中103例患者有66-81%达到IGA(0,1)且较基线改善≥2分,MEP中168例患者有32-38%达到该终点。
- 第68周时,MPP中83-89%的患者维持EASI 75,MEP中71-80%的患者达到EASI 75。
- MPP患者倾向于维持第16周记录的改善,MEP患者在整个维持期稳步改善。
- 未报告新的安全性信号,两个人群中大多数治疗中出现的不良事件为轻中度,安全性与lebrikizumab此前全球研究一致。
关键数值与推荐
- 第16周应答定义为IGA(0,1)且较基线改善≥2分和/或EASI 75。
- MPP第68周IGA(0,1)且较基线改善≥2分的比例为66-81%(103例),MEP为32-38%(168例)。
- MPP第68周EASI 75维持比例为83-89%,MEP达到EASI 75的比例为71-80%。
临床怎么用
- 对第16周达到IGA(0,1)和/或EASI 75应答的中重度特应性皮炎患者,可继续lebrikizumab 250 mg每2周或每4周联合TCS长期治疗以维持疗效。
- 对第16周未达应答的患者,继续lebrikizumab 250 mg每2周联合TCS仍可能逐步改善,不宜过早停药。
- 长期治疗中需常规监测不良事件,多数为轻中度,安全性与全球研究一致。
局限性
- 原文未报告盲法维持的具体实施细节。
- 原文未报告安慰剂对照在维持期的设置情况。
- 原文未报告长期疗效与安全性在每2周和每4周给药方案间的直接比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Moderate-to-severe atopic dermatitis (AD) affects the quality of life of patients. More treatment options are urgently needed to manage this chronic disease. Lebrikizumab is a monoclonal antibody that binds to interleukin-13, a key mediator in AD pathogenesis. In Japanese patients, lebrikizumab has been evaluated through week 16 in the randomized placebo-controlled phase III ADhere-J study. OBJECTIVES: To evaluate the long-term efficacy and safety of lebrikizumab in combination with topical corticosteroids (TCS) in the ADhere-J study. METHODS: Patients aged ≥12 years weighing ≥ 40 kg with moderate-to-severe AD and receiving either subcutaneous lebrikizumab 250 mg -every 2 weeks (Q2W)/every 4 weeks (Q4W) or placebo during the 16-week induction period were evaluated during the long-term maintenance period from week 16 to week 68. Responders achieved the co-primary endpoints at week 16: an Investigator's Global Assessment score of 0 or 1 [IGA (0,1)] with ≥ 2-point improvement from baseline and/or ≥ 75% improvement from baseline in Eczema Area and Severity Index (EASI 75). In this analysis, week 16 responders received lebrikizumab 250 mg Q2W or Q4W combined with TCS during the maintenance period (maintenance primary population; MPP); week 16 per-protocol nonresponders received lebrikizumab Q2W with TCS (maintenance escape population; MEP). Major endpoints included IGA (0,1) with ≥ 2-point improvement from baseline and EASI 75 through week 68. Other outcomes included quality of life, itch and serum thymus and activation-regulated chemokine. The trial was registered with ClinicalTrials.gov (NCT04760314). RESULTS: At week 68, 66-81% of 103 patients in the MPP and 32-38% of 168 patients in the MEP achieved IGA (0,1) with ≥ 2-point improvement from baseline. EASI 75 was maintained by 83-89% of patients in the MPP, while 71-80% of patients in the MEP achieved this outcome by week 68. Across treatment arms, patients in the MPP tended to maintain improvements recorded at week 16, while patients in the MEP steadily improved across the maintenance period. No new safety signals were reported, and most treatment-emergent adverse events were mild or moderate in severity in both populations. Safety outcomes were consistent with previous reports for lebrikizumab treatment in global studies. CONCLUSIONS: These results support the use of lebrikizumab in combination with TCS for the treatment of moderate-to-severe AD in the Japanese population in the long term. Atopic dermatitis (‘AD’ for short, also known as ‘eczema’) is a skin condition that causes inflamed skin, itchiness and dryness that can be difficult to treat. In some cases, people with AD are unable to work and can experience anxiety and depression. Many people live with this condition for their whole lives, so it is important to find treatments that can be used for a long time. In Japan, AD affects around 3% of adults and up to 13% of children. In this study, we looked at whether a new treatment for AD called ‘lebrikizumab’ could be used in the long term in Japanese patients aged 12 and older. We ran this study in Japan for 68 weeks. In the first 16 weeks, patients received an injection of either lebrikizumab every 2 or 4 weeks, or placebo (did not contain medicine) every 2 weeks. After 16 weeks, patients received lebrikizumab every 2 or 4 weeks. In addition, patients also used another type of treatment called ‘topical corticosteroids’ to match how they manage their disease in the real world. We measured the signs and symptoms of AD by asking doctors to judge their patients’ symptoms and by asking patients how bad their itch was and how it affected their lives. We found that lebrikizumab improved AD symptoms, in some patients after just 16 weeks of treatment. The improvements in these patients lasted when treatment was continued over the following year. Some patients still had symptoms of AD after 16 weeks of treatment. These patients had less severe symptoms by the end of the year when they continued to receive lebrikizumab treatment. Although these patients took longer to improve, the treatment helped. Overall, our study findings show that most side effects were mild, and the benefits of taking lebrikizumab appeared to outweigh the risks in Japanese patients with AD.
引用
- Katoh N, Tanaka A, Takahashi H, et al. Long-term management of moderate-to-severe atopic dermatitis with lebrikizumab and concomitant topical corticosteroids: a 68-week randomized double-blind placebo-controlled phase III trial in Japan (ADhere-J). Br J Dermatol. 2025. PMID: 39442013. doi:10.1093/bjd/ljae394
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。